Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis: Combining Real World and Clinical Trials for Totality of Evidence

被引：3
|
作者：
Khor, Yet H. [1 ,2 ,3 ]
机构：
[1] Univ Melbourne, Dept Resp & Sleep Med Austin Hlth, Melbourne, Vic, Australia
[2] Univ Melbourne, Inst Breathing & Sleep, Fac Med, Melbourne, Vic, Australia
[3] Monash Univ, Cent Clin Sch, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia
来源：
CHEST | 2021年 / 160卷 / 05期
关键词：
PIRFENIDONE;
D O I：
10.1016/j.chest.2021.07.033
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：1589 / 1591
页数：3
相关论文
共 50 条
  • [31] Combination antifibrotic therapy in Idiopathic Pulmonary Fibrosis patients: real life experience in an ILD Unit.
    Martinez Besteiro, E.
    Beceiro, M. J.
    Churruca Arrospide, M.
    Mouhtar, D.
    Pelaez, A.
    Alonso, T.
    Ancochea, J.
    Valenzuela, C.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [32] The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
    Kette, Stefano
    Reccardini, Nicolo
    Salton, Francesco
    Confalonieri, Paola
    Andrisano, Alessia
    Chianese, Maria
    De Nes, Anna
    Maggisano, Marta
    Galantino, Alessandra
    Nicolosi, Salvatore
    Mari, Marco
    Salotti, Andrea
    Angoni, Darina
    Chernovsky, Maria
    Hughes, Michael
    Confalonieri, Marco
    Mondini, Lucrezia
    Ruaro, Barbara
    PHARMACEUTICALS, 2025, 18 (03)
  • [33] Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis
    Naoi, Hyogo
    Suzuki, Yuzo
    Mori, Kazutaka
    Aono, Yuya
    Kono, Masato
    Hasegawa, Hirotsugu
    Yokomura, Koshi
    Inoue, Yusuke
    Hozumi, Hironao
    Karayama, Masato
    Furuhashi, Kazuki
    Enomoto, Noriyuki
    Fujisawa, Tomoyuki
    Nakamura, Yutaro
    Inui, Naoki
    Nakamura, Hidenori
    Suda, Takafumi
    THORAX, 2022, 77 (07) : 727 - 730
  • [34] Effect of Antifibrotic Therapy on Mortality and Survival Outcomes in Idiopathic Pulmonary Fibrosis
    Schecter, S.
    Koppurapu, V. S.
    Zemkova, Y.
    Barber, D.
    Shim, Y.
    Laroia, A.
    Lee, C.
    Ussavarungsi, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [35] Lung Cancer Incidence in Patients on Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
    Kadura, S.
    Barakat, A.
    Breeze, J.
    LaCamera, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [36] Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
    Qiu, Ying
    Zhao, Ruizhi
    Elpers, Brandon
    Wang, Yuexi
    Xie, Lin
    Tang, Jackson
    Fischer, Aryeh
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [37] Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences
    Harari, Sergio
    Caminati, Antonella
    EUROPEAN RESPIRATORY REVIEW, 2015, 24 (137): : 420 - 427
  • [38] The future of clinical trials in idiopathic pulmonary fibrosis
    Spagnolo, Paolo
    Maher, Toby M.
    CURRENT OPINION IN PULMONARY MEDICINE, 2024, 30 (05) : 494 - 499
  • [39] The Future of Clinical Trials in Idiopathic Pulmonary Fibrosis
    Podolanczuk, Anna J.
    Richeldi, Luca
    Martinez, Fernando J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (18): : 1554 - 1555
  • [40] The big clinical trials in idiopathic pulmonary fibrosis
    Luppi, Fabrizio
    Spagnolo, Paolo
    Cerri, Stefania
    Richeldi, Luca
    CURRENT OPINION IN PULMONARY MEDICINE, 2012, 18 (05) : 428 - 432
12345